Duloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation

Basit Öğe Kaydı
dc.authorid0000-0001-5254-2563
dc.contributor.authorÖzcan, Levent
dc.contributor.authorPolat, Emre Can
dc.contributor.authorÖtünçtemür, Alper
dc.contributor.authorÖzbek, Emin
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:57:03Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:57:03Z
dc.date.issued2015
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı
dc.descriptionWOS: 000348995500011
dc.descriptionPubMed ID: 25557853
dc.description.abstractIn the current analysis due to the mechanism of effect, we evaluated the treatment benefit of duloxetine 40 mg comparing with paroxetine 20 mg, based on its effects on personal distress and interpersonal difficulty related to ejaculation, perceived control over ejaculation, and satisfaction with sexual intercourse, as well as the patient-reported global impression of change in premature ejaculation (PE) and the effect on intravaginal ejaculatory latency times (IELT) in men with premature ejaculation. The study included 80 married male patients diagnosed with lifelong PE. A total of 80 patients were randomly distributed into two groups of 40 patients each. Group 1 patients received 40 mg duloxetine once a day for a month. Group 2 patients received 20 mg paroxetine once a day for a month. International index of erectile function questionnaire (IIEF) and IELT and PE profile were recorded before and after treatment. Comparing the groups' mean treatment IELT, there was no difference between groups. The IELT increase from baseline to treatment was 117 % in the duloxetine group (P < 0.001) and 126 % in the paroxetine group (P < 0.001). There was no statistical difference between two groups in terms of IELT increase (P > 0.05). Also, there was no statistically significant difference between two groups at baseline IIEF to treatment IIEF scores. All PEP measures improved significantly with duloxetine and paroxetine groups (P < 0.001). We think that duloxetine is safe and effective for the treatment for premature ejaculation.
dc.identifier.citationÖzcan, L., Polat, E. C., Ötünçtemür, A. ve Özbek, E. (2015). Duloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation. 47(2), 283-287. https://dx.doi.org/10.1007/s11255-014-0905-9
dc.identifier.doi10.1007/s11255-014-0905-9
dc.identifier.endpage287
dc.identifier.issn0301-1623
dc.identifier.issn1573-2584
dc.identifier.issue2
dc.identifier.scopusqualityQ2
dc.identifier.startpage283
dc.identifier.urihttps://dx.doi.org/10.1007/s11255-014-0905-9
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2884
dc.identifier.volume47
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofInternational Urology and Nephrologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectPremature Ejaculation
dc.subjectIntravaginal Ejaculatory Latency Times (IELT)
dc.subjectDuloxetine
dc.subjectParoxetine
dc.titleDuloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
polat, emre-2015.pdf
Boyut:
214.39 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu